Poon Andrew C, Matsuyama Arata, Mutsaers Anthony J
Department of Biomedical Sciences (Poon, Matsuyama, Mutsaers), Department of Clinical Studies (Mutsaers), Ontario Veterinary College, University of Guelph, Guelph, Ontario N1G 2W1.
Can Vet J. 2020 Mar;61(3):301-308.
Osteosarcoma (OSA) is an aggressive primary bone tumor in the domestic dog that most often occurs within the appendicular skeleton. Despite the use of adjuvant chemotherapy, most dogs succumb to metastatic disease within 1 year of diagnosis. To improve this outcome, substantial research is currently focused on investigating novel therapies. Herein, we review emerging treatments and clinical trials that, if proven efficacious, could revolutionize the standard of care for canine appendicular OSA. This article includes a critical perspective on the safety, efficacy, and limitations of select immunotherapy, virotherapy, radiotherapy, targeted therapy, and personalized medicine trials, all of which reflect similar investigations taking place in human oncology. These clinical trials represent a major evolution in the overall approach to therapy for dogs with appendicular OSA that could have significant implications for improving survival.
骨肉瘤（OSA）是家犬中一种侵袭性原发性骨肿瘤，最常发生于四肢骨骼。尽管使用了辅助化疗，但大多数犬在诊断后1年内会死于转移性疾病。为改善这一结果，目前大量研究集中在探索新疗法。在此，我们综述了新兴治疗方法和临床试验，如果这些方法被证明有效，可能会彻底改变犬四肢骨肉瘤的治疗标准。本文对选定的免疫疗法、病毒疗法、放射疗法、靶向疗法和个性化医学试验的安全性、有效性和局限性进行了批判性分析，所有这些都反映了人类肿瘤学中正在进行的类似研究。这些临床试验代表了犬四肢骨肉瘤整体治疗方法的重大演变，可能对提高生存率有重大意义。
